← Back to Clinical Trials
Recruiting NCT06773598

NCT06773598 Validation of a Machine Learning Model Based on MR for the Prediction of Prostate Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06773598
Status Recruiting
Phase
Sponsor IRCCS Azienda Ospedaliero-Universitaria di Bologna
Condition Prostate Cancer
Study Type OBSERVATIONAL
Enrollment 1,100 participants
Start Date 2024-05-21
Primary Completion 2028-10

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,100 participants in total. It began in 2024-05-21 with a primary completion date of 2028-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this observational study is to validate a clinically significant predictive machine learning model based on the processing of images RMmp (Multiparametric Magnetic Resonance Imaging). To be validated the model should be evaluated on: * Specificity (SP): is the probability of a negative test result, conditioned on the individual truly being negative * Sensitivity (SN): is the probability of a positive test result, conditioned on the individual truly being positive

Eligibility Criteria

Inclusion Criteria: * Participants aged 18 at the time of examination * Obtaining informed consent * Presence of one or more lesions classified as PI-RADSv2.1 ≥ 1 at a prostate RMmp at the IRCCS Azienda Ospedaliero-Universitaria in Bologna * Indication for TRUS biopsy by fusion technique integrated with systematic biopsy at the IRCCS Azienda Ospedaliero-Universitaria in Bologna Exclusion Criteria: * Previous prostate surgery or hormone therapy * Technically sub-optimal investigations for the presence of artifacts (hip prosthesis, movement of the endorectal probe, etc.)

Contact & Investigator

Central Contact

Caterina Gaudiano, MD

✉ caterina.gaudiano@aosp.bo.it

📞 +39 0515142307

Principal Investigator

Caterina Gaudiano, MD

PRINCIPAL INVESTIGATOR

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Frequently Asked Questions

Who can join the NCT06773598 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06773598 currently recruiting?

Yes, NCT06773598 is actively recruiting participants. Contact the research team at caterina.gaudiano@aosp.bo.it for enrollment information.

Where is the NCT06773598 trial being conducted?

This trial is being conducted at Bologna, Italy.

Who is sponsoring the NCT06773598 clinical trial?

NCT06773598 is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. The principal investigator is Caterina Gaudiano, MD at IRCCS Azienda Ospedaliero-Universitaria di Bologna. The trial plans to enroll 1,100 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology